Collectively, these data offer a rationale for clinical trials to assess the efficacy of JAK2 and PP2A-dependent autophagy inhibition in MPN patients expressing JAK2V617F mutant. The gene discussed is PTPA; the disease is myeloproliferative neoplasm.